These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

216 related items for PubMed ID: 26314822

  • 1. Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey.
    Longhurst HJ, Aberer W, Bouillet L, Caballero T, Fabien V, Zanichelli A, Maurer M, IOS Investigators.
    Allergy Asthma Proc; 2015; 36(5):399-406. PubMed ID: 26314822
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
    Maurer M, Longhurst HJ, Fabien V, Li HH, Lumry WR.
    Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
    [Abstract] [Full Text] [Related]

  • 4. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
    Baş M, Greve J, Hoffmann TK, Reshef A, Aberer W, Maurer M, Kivity S, Farkas H, Floccard B, Arcoleo F, Martin L, Sitkauskiene B, Bouillet L, Schmid-Grendelmeier P, Li H, Zanichelli A.
    Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment.
    Maurer M, Aberer W, Bouillet L, Caballero T, Fabien V, Kanny G, Kaplan A, Longhurst H, Zanichelli A, I O S Investigators.
    PLoS One; 2013 Nov; 8(2):e53773. PubMed ID: 23390491
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
    Lumry WR, Farkas H, Moldovan D, Toubi E, Baptista J, Craig T, Riedl M.
    Int Arch Allergy Immunol; 2015 Nov; 168(1):44-55. PubMed ID: 26556097
    [Abstract] [Full Text] [Related]

  • 9. Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.
    Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, Riedl M, Li H, Craig T, Bloom BJ, Reshef A.
    Ann Allergy Asthma Immunol; 2011 Dec; 107(6):529-37. PubMed ID: 22123383
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
    Caballero T, Aberer W, Longhurst HJ, Maurer M, Zanichelli A, Perrin A, Bouillet L, Andresen I, IOS Study Group.
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444
    [Abstract] [Full Text] [Related]

  • 12. Successful long-term treatment with the bradykinin B2 receptor antagonist icatibant in a patient with hereditary angioedema.
    Greve J, Hoffmann TK, Schuler P, Lang S, Chaker A, Bas M.
    Int J Dermatol; 2011 Oct; 50(10):1294-5. PubMed ID: 21950301
    [Abstract] [Full Text] [Related]

  • 13. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
    Longhurst HJ, Zanichelli A, Caballero T, Bouillet L, Aberer W, Maurer M, Fain O, Fabien V, Andresen I, IOS Study Group.
    Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
    [Abstract] [Full Text] [Related]

  • 14. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
    Otani IM, Lumry WR, Hurwitz S, Li HH, Craig TJ, Holtzman NS, Iandoli MI, Tucker J, Riedl MA, Zuraw BL, Banerji A.
    J Allergy Clin Immunol Pract; 2017 Apr; 5(2):442-447.e1. PubMed ID: 27818136
    [Abstract] [Full Text] [Related]

  • 15. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
    Bouillet L, Boccon-Gibod I, Launay D, Gompel A, Kanny G, Fabien V, Fain O, IOS Study Group.
    Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
    [Abstract] [Full Text] [Related]

  • 16. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.
    Aberer W, Maurer M, Reshef A, Longhurst H, Kivity S, Bygum A, Caballero T, Bloom B, Nair N, Malbrán A.
    Allergy; 2014 Mar; 69(3):305-14. PubMed ID: 24438203
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.
    Farkas H, Reshef A, Aberer W, Caballero T, McCarthy L, Hao J, Nothaft W, Schranz J, Bernstein JA, Li HH.
    J Allergy Clin Immunol Pract; 2017 Mar; 5(6):1671-1678.e2. PubMed ID: 28601641
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.